Assessing the use of SABR in stage 1 non-small cell lung cancer in England: the use of the National Radiotherapy Data Set

Lung Cancer ◽  
2018 ◽  
Vol 115 ◽  
pp. S22
Author(s):  
I. Phillips ◽  
V. Ezhil ◽  
R. Brock ◽  
K. Henson ◽  
S. Lawton
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Data Set ◽  
Stage 1

scholarly journals SURVIVAL IN COPD PATIENTS WITH STAGE 1 NON-SMALL CELL LUNG CANCER

CHEST Journal ◽  
2020 ◽  
Vol 158 (4) ◽  
pp. A1463
Author(s):  
Nirosshan Thiruchelvam ◽  
Yash Sarda ◽  
Xiaozhen Han ◽  
Xiaofeng Wang ◽  
Peter Mazzone
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Copd Patients ◽  
Stage 1

scholarly journals Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set

2019 ◽  
pp. 1-13 ◽  
Author(s):  
Sandra D. Griffith ◽  
Rebecca A. Miksad ◽  
Geoff Calkins ◽  
Paul You ◽  
Nicole G. Lipitz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Large Scale ◽  
Progression Free Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
Data Set ◽  
End Points

PURPOSE Large, generalizable real-world data can enhance traditional clinical trial results. The current study evaluates reliability, clinical relevance, and large-scale feasibility for a previously documented method with which to characterize cancer progression outcomes in advanced non–small-cell lung cancer from electronic health record (EHR) data. METHODS Patients who were diagnosed with advanced non–small-cell lung cancer between January 1, 2011, and February 28, 2018, with two or more EHR-documented visits and one or more systemic therapy line initiated were identified in Flatiron Health’s longitudinal EHR-derived database. After institutional review board approval, we retrospectively characterized real-world progression (rwP) dates, with a random duplicate sample to ascertain interabstractor agreement. We calculated real-world progression-free survival, real-world time to progression, real-world time to next treatment, and overall survival (OS) using the Kaplan-Meier method (index date was the date of first-line therapy initiation), and correlations between OS and other end points were assessed at the patient level (Spearman’s ρ). RESULTS Of 30,276 eligible patients,16,606 (55%) had one or more rwP event. Of these patients, 11,366 (68%) had subsequent death, treatment discontinuation, or new treatment initiation. Correlation of real-world progression-free survival with OS was moderate to high (Spearman’s ρ, 0.76; 95% CI, 0.75 to 0.77; evaluable patients, n = 20,020), and for real-world time to progression correlation with OS was lower (Spearman’s ρ, 0.69; 95% CI, 0.68 to 0.70; evaluable patients, n = 11,902). Interabstractor agreement on rwP occurrence was 0.94 (duplicate sample, n = 1,065) and on rwP date 0.85 (95% CI, 0.81 to 0.89; evaluable patients n = 358 [patients with two independent event captures within 30 days]). Median rwP abstraction time from individual EHRs was 18.0 minutes (interquartile range, 9.7 to 34.4 minutes). CONCLUSION We demonstrated that rwP-based end points correlate with OS, and that rwP curation from a large, contemporary EHR data set can be reliable, clinically relevant, and feasible on a large scale.

Effect of age on impact of adjuvant chemotherapy for resected non-small cell lung cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 7539-7539
Author(s):  
Apar Kishor Ganti ◽  
Christina D. Williams ◽  
Ajeet Gajra ◽  
Michael J. Kelley
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Older Patients ◽  
Early Stage ◽  
Small Cell ◽  
Small Cell Lung ◽  
Younger Patients ◽  
Stage 1

7539 Background: Adjuvant chemotherapy (AC) is considered standard of care in patients with resected stages 2 and 3 non-small cell lung cancer (NSCLC). However data regarding its utility in older patients are sparse. This analysis was conducted to evaluate the role of AC in older patients with early stage NSCLC. Methods: We conducted a retrospective analysis of patients with stages 1-3 NSCLC between 2001 and 2008 in the VA Central Cancer Registry. Patients were divided into two groups based on age: <70 yrs and ≥70 yrs. Descriptive statistics were used to examine patterns of AC use and to obtain survival rates associated with use of AC in the two age groups. Chi-square was used to compare distributions. Results: Of the 10,036 patients who underwent surgical resection, 3958 (39.4%) were ≥70 yrs, while 6078 were <70 yrs old. Overall, 11.2% of older patients (6.3% - stage 1, 21% - stage 2, 26.2% - stage 3) and 22.3% of younger pts (11.6% - stage 1, 41.1% - stage 2, 47.1% - stage 3) received AC. Of the patients who received AC, a greater proportion of younger patients received platinum-based AC (91.8 vs 86.4% vs; p=0.0008). Also, in each stage younger patients had a better 3 yr overall survival (OS) (Stage 1-69.2 vs 58%, stage 2 – 52.8 vs 39.1%, stage 3 – 42.5 vs 33.7%). Younger patients with stages 2 and 3 NSCLC who received AC had improved 3 yr OS (58.8 vs 48.6%; p=0.0009 and 48.8 vs 36.9%; p=0.0002 respectively). There was no difference in 3 yr OS for older patients based on AC when all stages were included. For patients with stages 2 and 3, a larger proportion of younger patients received cisplatin-based AC (11.3 vs 3.5%). Older patients with stages 2 and 3, who received cisplatin-based AC had a better 3 yr OS compared to those who received carboplatin-based AC or no AC (55.3 vs 42.2 vs 35.3% respectively; p=0.01). Similarly cisplatin-based AC had an improved 3 yr OS in younger patients with stages 2 and 3 NSCLC (61.4 vs 52 vs 43.4% respectively; p=0.0001). Conclusions: This analysis suggests that older patients do not benefit from AC after resection of stage 1-3 NSCLC to the same degree as younger patients. This differential effect may be due to less common use of cisplatin among older patients. Multivariate analyses are planned.

Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial

Lung Cancer ◽  
2005 ◽  
Vol 48 (2) ◽  
pp. 241-246 ◽  
Author(s):  
Jonathan D’Cunha ◽  
James E. Herndon ◽  
Debra L. Herzan ◽  
G. Alexander Patterson ◽  
Leslie J. Kohman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prospective Trial ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pathologic Staging ◽  
Stage 1

Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC)

Lung Cancer ◽  
2014 ◽  
Vol 85 (1) ◽  
pp. 59-65 ◽  
Author(s):  
John T. Lucas ◽  
Jeffrey G. Kuremsky ◽  
Mike Soike ◽  
William W. Hinson ◽  
William T. Kearns ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Stereotactic Body Radiotherapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Node Negative ◽  
Stage 1

scholarly journals Ferroptosis-related gene AKR1C1 predicts the prognosis of non-small cell lung cancer

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Fangfang Huang ◽  
Yushi Zheng ◽  
Xiaoling Li ◽  
Hui Luo ◽  
Lianxiang Luo
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
The Cancer Genome Atlas ◽  
Nsclc Cell ◽  
Related Gene ◽  
Small Cell Lung ◽  
Data Set

Abstract Background Ferroptosis is a newly discovered mode of cell death distinct from apoptosis and necrosis, and its activation contributes to anticancer therapy in a variety of cancers. However, the prognostic value of ferroptosis-related genes in non-small cell lung cancer (NSCLC) remains to be further investigated. Methods NSCLC transcriptome mRNA-seq data set and corresponding clinical data set were downloaded from the Cancer Genome Atlas (TCGA). Then, bioinformatics approaches were subsequently employed to identify potential prognostic markers. Finally, the effects of candidate markers on NSCLC cell proliferation, migration, and ferroptosis were assessed by CCK8, colony formation, wound-healing assay, and functional assays related to ferroptosis. Results A total of 37 common differentially expressed genes were screened based TCGA database. Six overall survival associated genes (ENPP2, ULK1, CP, LURAP1L, HIC1, AKR1C1) were selected to build survival model, of which hub gene AKR1C1 was with high expression and low ferroptosis level in NSCLC tumor. Further research showed that AKR1C1 was related with many pathways involved in the process of ferroptosis and associated with diverse cancer-infiltrating immune cells. Moreover, the results of in vitro experiments indicated that the expression of AKR1C1 was upregulated in NSCLC cell lines, and silencing AKR1C1 can inhibit the proliferation and migration of NSCLC cells and promote the occurrence of ferroptosis. Conclusions Our study revealed the potential role of ferroptosis-related gene AKR1C1 in NSCLC, which can be used for prognostic prediction in NSCLC.

scholarly journals VATS-Lobectomy: Ready for Routine Use in Stage 1 and 2 Non-Small Cell Lung Cancer?

2017 ◽  
Vol 65 (S 01) ◽  
pp. S1-S110
Author(s):  
T. Sandhaus ◽  
T. Bönsch ◽  
M. Grallert ◽  
T. Doenst ◽  
M. Steinert
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Vats Lobectomy ◽  
Stage 1

scholarly journals MiR-516a-5p inhibits the proliferation of non-small cell lung cancer by targeting HIST3H2A

2019 ◽  
Vol 33 ◽  
pp. 205873841984148 ◽  
Author(s):  
Xiang-Yun Ye ◽  
Ling Xu ◽  
Shun Lu ◽  
Zhi-Wei Chen
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Recurrence ◽  
Small Cell ◽  
Independent Prognostic Factor ◽  
The Cancer Genome Atlas ◽  
Small Cell Lung ◽  
Data Set

The dysregulation of microRNAs (miRNAs) is associated with the pathogenesis of non-small cell lung cancer (NSCLC). However, the mechanisms by which miR-516a-5p contributes to NSCLC remain unclear. The association between miR-516a-5p expression and the clinicopathological characteristics and prognosis in patients with NSCLC was analyzed by The Cancer Genome Atlas (TCGA) data set. The targets of miR-516a-5p were identified by bioinformatic analysis and luciferase report assay. MTT and soft agar assays were conducted to investigate the function of miR-516a-5p in NSCLC cells. We found that the expression of miR-516a-5p was decreased in NSCLC tissues and associated with the age, pathological stage, and tumor size, acting as an independent prognostic factor of tumor recurrence in patients with NSCLC. Restoration of miR-516a-5p inhibited the cell viability and anchorage-independent growth of NSCLC cells, but its inhibitor had the opposite effects. Histone cluster 3 H2A (HIST3H2A) was further identified as a direct target of miR-516a-5p and displayed a negative correlation with miR-516a-5p expression in NSCLC tissues. Overexpression of HIST3H2A reversed the anti-proliferation effects induced by miR-516a-5p and acted as an independent prognostic factor of poor survival in patients with NSCLC. Altogether, our findings demonstrate that miR-516a-5p may function as a tumor suppressive factor in NSCLC cells by targeting HIST3H2A and might represent a potential indicator of tumor recurrence in patients with NSCLC.

Sign in / Sign up

Export Citation Format

Share Document